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reactivations has been observed so far under the profound
“innate control.” Up to date, none of the patients developed
aGVHD > grade II.
Conclusion: ATG Busulfan Fludarabine is a low toxicity
platform for abTCR-depleted transplantations, resulting in a
swift reconstitution of innate cells (NK cells and gd T cells)
the ﬁrst 6 months post transplantation. This transplantation
strategy can serve as a tool for future immunological in-
terventions such as a pre-emptive DLI or transfer of geneti-
cally modiﬁed T cells.394
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Objective: To compare Overall Survival (OS), Treatment
Related Mortality (TRM), and Relapse Rate (RR) between
myeloablative conditioning (MAC) and reduced intensity
conditioning (RIC) regimens in patients with high/interme-
diate risk disease status. The hypothesis to be tested is that
HCT-CI can be effectively used to decide on the preference of
conditioning regimen and that RICwill decrease TRMwithout
increasing relapse so that OS will be improved even in high/
intermediate risk disease status patients with high HCT-CI.
Patients and Methods: Patients with high HCT-CI ( 3)
underwent RIC regimen and those with low HCT-CI ( 2)
underwent MAC regimen despite high/intermediate risk
disease status. We analyzed the outcome of 92 patients with
high or intermediate risk disease status (CIBMTR criteria)
who underwent Allo-HCT at our institution between the
years 2009 and 2013 inclusive. RIC regimen consisted of IV
Fludarabine 30mg/m2/day infused over 30minutes for 5 days
on days -6 through -2 and IV Busulfan 3.2 mg/kg/day on days
-3 and -2 (infusion rate 80 mg mg/hour). MAC regimen
consisted of IV Fludarabine 50mg/m2/day infused over 1
hour on days -6 through -2, IV Busulfan 3.2mg/m2/kg/day on
days -5 through -2 (infusion rate 80mg/hr), and TBI 200 cGY
on days -2 and -1. All patients received Thymoglobulin at a
total dose of 4.5 mg/kg or 6 mg/kg administered in divided
doses on days -2, -1 and 0. Post-transplantation graft versus
host disease (GVHD) prophylaxis consisted of tacrolimus and
mycophenolate mofetil. Diagnoses included Acute Lympho-
blastic Leukemia (n¼4), Myeloproliferative disorder (n¼7),
Hodgkin’s Lymphoma (n¼8), Myelodysplastic Syndrome
(n¼20), Acute myeloid leukemia (n¼25), and Non-Hodgkin’s
Lymphoma (n¼28). Median age of the recipients was 52.1
years. The HCT-CI was high ( 3) in 41 recipients (47%) and
75 patients (83%) were in high risk disease status.
Results: At a median follow up of 13.2 months, the OS for
patients undergoing RIC was 74.3% compared to 38.1% with
MAC (p¼0.014). The cumulative incidence of TRM at 12
months was 27.6% in patients undergoing MAC compared to
<1% in RIC (p¼0.041). Relapse relatedmortality at 12months
in RIC (25.7%) compared to MAC (50.5%) was not statistically
different (p¼0.206).
Conclusion: Our data demonstrates that use of HCT-CI is a
simple but effective way to appropriately stratify patients
with high/intermediate disease risk status to a particular
conditioning regimen. The use of RIC in patients with high
HCT-CI is non-inferior to MAC with our institutional data
showing RIC is associated with low TRM, improved OSwithout any statistically signiﬁcant increase in mortality
from disease progression or relapse. Prospective studies are
necessary to validate these ﬁndings.395
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Background: AHCT remains the only curative option for MM
despite improved survival with novel agents. We analyzed
our single center experience of AHCT in MM over the past
decade and examined factors associated with outcomes.
Methods: The outcomes of 77 consecutive MM patients
receiving allotransplants from matched sibling (n¼69) or
unrelated donors (n ¼8) between 2002 and 2013 at our
institution were analyzed. The primary objectives were to
compare overall survival (OS), progression free survival,
(PFS), and non-relapse mortality (NRM) in patients based on
biologic disease risk and conditioning regimen intensity. 60
pts. received allotransplant after non-myeloablative regi-
mens (regimen 1) e low dose 200-cGy total body irradiation
(TBI) +/-Fludarabine (n ¼ 52) or Cyclophosphamide + Flu-
darabine (n¼8) while 17 received higher intensity condi-
tioning (regimen 2) consisting of Fludarabine + Melphalan
140 mg/2 (11) or Cyclophosphamide + TBI (6).
Results: Patient, disease and transplant related characteris-
tics are given in Table 1. Median follow up of survivors was
49.4 months. 27 (35.1%) had high-risk cytogenetics e t
(4:14), 17p deletion, Chr 1 abnormality, or t (14:16). 96%
had prior auto transplant with 17(22%) relapsing after auto
transplant.
On multivariate analysis, older age (HR 1.06 95% CI 1.015,
1.120, p¼0.0112), lack of a complete remission (CR) at allo-
transplant (HR0.1595%CI 0.046, 0.485, p¼.0015 inCR), longer
interval from autologous transplant to AHCT (6.0 mvs. 5.2 m)
(HR 1.04, 95%CI 1.008, 1.072, p¼0.01) and CMV reactivation
(HR 3.2, 95% CI 1.41, 7.52,p¼0.005) were signiﬁcant for higher
mortality. CR at the transplant was associated with superior
PFS (HR for treatment failure 0.332, p¼0.041). Increasing age
(HR, 1.07 p¼0.047) and non-CR status at transplant (HR for
CR - 0.164, 95% CI .035, .770, p¼0.021) were associated with
higher NRM. High-risk-disease and conditioning intensity
were not associated with outcomes (Fig 1, 2).
Conclusions: The adverse effect of high-risk genetics may be
overcome by the allogeneic effect irrespective of condition-
ing intensity. Allotransplant beneﬁted younger patients and
those in CR at the time of transplant and with short intervals
from prior auto-grafts. No plateau in survival was demon-
strated.
Table 1
Variables Total,
N¼77
Regimen 1,
N¼ 60
Regimen 2,
N¼17(%)
P
value
Age, years
median (range)
52(23-69) 52.5(32-69) 52(23-61) 0.40
Female, n (%) 28(36.4) 26(43.3) 2(11.8) 0.017
FISH risk, n(%) 0.55
Low 50(64.9) 40(66.7) 10(58.8)
High 27(35.1) 20(33.3) 7(41.2)
Time from auto
to AHCT, months
median (range)
5.2(3.3-75.2) 5.0(3.0-47.1) 6.3(4.1-75.2) 0.02
Response status
at transplant,n(%)
0.21
CR 23 (29.9) 15 (25.0) 8 (47.1)
PR 47 (61.0) 39 (65.0) 8 (47.1)
SD 7 (9.1) 6 (10.0) 1 (5.9)
CMV reactivation,
n(%)
14 (18.2) 9 (15.0) 5 (29.4) 0.28
Figure 1. Overall survival by conditioning regimen intensity
Figure 2. Progression free survival by FISH risk
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The Clinical Outcome of Allogeneic Hematopoietic Stem
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Background: Treatment with TKIs has greatly improved the
outcome of patients with Ph+ALL. However most older pa-
tients are excluded from clinical studies, the curative po-
tential of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has not been fully analyzed. We examine the
clinical features and transplant outcome of elderly Ph+ALL
patients in the era of TKI.
Methods: We analyzed the data from 30 Ph+ALL patients
aged 50 years or older who had used TKI before allo-HSCT.
Results: The median age was 59 years (range<r>: 50-71);15
patients (50%) were older than 60 years. Subjects comprised
13 males and 17 females. The disease status at allo-HSCT was
complete remission (CR) in 23 patients and non-CR in 7 pa-
tients. Before HSCT, 23 patients received imatinib-based
chemotherapy, and 7 patients received dasatinib-based
chemotherapy. The majority of the donors were HLA-
matched unrelated (n¼16) and related (n¼6), followed by
mismatched unrelated cord blood (n¼7). Median follow-up
for survivors was 247 days (r:16-4,156). The median HCT
comorbidity index score was 1 (r:0-3). Median white blood
cell count at diagnosis was 26.3109/L(r: 4.2-301.9 109/L).
Type of BCR breakpoint was minor in 23 patients (67%).
Graft-versus-host-disease (GVHD) prophylaxis was calci-
neurin inhibitor-based in all patients (CsA:13 patients,
FK506:17). Eleven patients received reduced-intensity con-
ditioning regimens, nineteen patients received myeloa-
blative conditioning regimens. Themedian duration from the
diagnosis to HSCTwas 197 days (95-763). No patient received
TKIs after HSCT.
The probability of overall survival (OS) and disease free
survival (DFS) at 1 year after HSCT were 46.0% and 42.0%,
respectively. These results were not statistically different
compared to the 35 patients aged under 50 years who had
used TKIs before allogeneic HSCT. Multivariate analysis
showed that the factor to inﬂuence OS was disease status (CR
or nonCR) (p¼0.01). Cumulative incidence of nonrelapse
mortality (NRM) was 23.1% at 100 days after HSCT, and 52.0%
at 1 year. The cumulative incidence of acute graft-versus-
host disease <GVHD> (grade II-zW) and chronic GVHD at 1
year were 51.8% and 23.1%. Four patients relapsed after HSCT
with a median of 329 days (r:112-475 days). The estimated
cumulative incidence of relapse at 1 year was 8%. These
outcomes (OS, DFS, NRM, relapse rate) were not signiﬁcantly
different when stratiﬁed by age groups (under vs. older than
60 years old). Increasing age was not associated with in-
creases in acute or chronic GVHD. All of patients aged more
than 60 years had HCT comorbidity index scores of 2.
Eighteen patients died at 139 days (r:16-1,219). The main
cause of death was infection (10 patients).
Conclusion: Allo-HSCT for elderly Ph+ALL patients may be
one of the promising strategy. Allo-HSCT would be effec-
tive option for carefully selected patients aged 60 or older
with Ph+ALL.397
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Bone marrow transplantation has the potential to improve
the outcome of many indications other than cancer, but this
is hampered by the associated complications. Myeloid pro-
genitor cells (MP), which produce a transient engraftment
